NTM Program
Non-Tuberculous Mycobacterial Infections
Pre-clinicalActive
Key Facts
About ArrePath
ArrePath is a private, preclinical-stage biotech applying a proprietary AI/ML platform to accelerate and de-risk small molecule drug discovery. The company's core innovation lies in its ability to integrate disparate assay data and tightly embed AI into the entire discovery workflow, claiming at least 3x greater efficiency in identifying progressible compounds. To date, ArrePath has generated early validation with the discovery of two novel antibiotic classes and is actively expanding its pipeline into respiratory medicine and other therapeutic areas.
View full company profile